Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension
Sildenafil for Oral Suspension had annual sales of USD 65 million in the United States according to IQVIA data (IQVIA MAT Aug 2022).
Sildenafil for Oral Suspension had annual sales of USD 65 million in the United States according to IQVIA data (IQVIA MAT Aug 2022).
The company will address the observations within a stipulated timeline working with the regulators
The combination of Optym, Emmes' ophthalmology certification unit, and Clinical Edge will make the organization a leader in ophthalmic certification and training services
The two-day meeting in the city was organized in collaboration with the University of Birmingham, Christian Medical College Ludhiana, and Birmingham Clinical Trials Unit
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
Transformation to pure-play Innovative Medicines company nears completion
The companies will leverage their respective proprietary technology platforms
This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.
The ANDA was filed as 'First to File' submission on NCE-1 date.
Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.
Subscribe To Our Newsletter & Stay Updated